Skip to main content

Development of biomaterials with improved resistance to infection

Objective



Medical Devices represent half of the nosocomial complications in the hospital (25 40 % of intravenous catheters are infected after 5 7 days). They are related to a relative affinity of bacteria to adhere on an artificial surface, and to develop a biofilm structure which isolate microorganisms from conventional therapies.

End users and Industrials are highly concerned by morbidity and health care costs of infection. Although antibiotic bounding and silver treatment of the materials have already been proposed, their efficacy, safety and long term performances have not been established. This fundamental research program is dealing with the screening of more than 10 different surface treatment for polymers in order to design an "anti bacterial" interface.

These techniques of potential interest in developping antibacterial surfaces will include: Design of specific antibacterial activity (silver, quaternary ammonium, carbon like coating + Ag, silver iodide, antiseptics).
Grafting of biological molecules within the bulk or on the surface (heparin is of high potential interest).
Development of non fouling surfaces concept (PEO like, PEO
repelling, teflon like, suprahydrophilic, microstructurated)
The activity of these materials will be screened on bacterial strains and in conditions representative of the clinical use. A fundamental approach of biofilm expression and regulation according to the different polymeric surfaces and treatments is included as an important step for the understanding of the effects.

The project will be in a second time (after month 20) restricted to efficient surface treatments and to those for which the risk benefit ratio is acceptable.Polymeric changes induced by the treatment, optimization of sterilization conditions will be investigated.
5 academic partners who developped and fully control these
technologies and 5 industrial partners, including 2 CRO's, will participate to this extensive project. Due to its important impact, the project is exceeding 30 % of the total cost allowed for basic research projects. However, this size expresses also the need for an EU level programme since no single partner would be able to develop it individualy.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

BIOMATECH S.A.
Address
Rue Pasteur 115, Z.i. L'islon
38670 Chasse Sur Rhone
France

Participants (10)

Bellco SpA
Italy
Address
Via Camurana 1/A
41037 Mirandola Modena
Enterprise Ireland - Trading as Bioresearch Ireland
Ireland
Address
Glasnevin
9 Dublin
Ergo S.A.
Greece
Address
15,Ag Orous Street
15123 Athens
Humboldt-Universität zu Berlin
Germany
Address
1,Augustenburger Platz
13353 Berlin
ROYAL INSTITUTE OF TECHNOLOGY
Sweden
Address
Teknikringen 56-58
100 44 Stockholm
UNIVERSITE CLAUDE BERNARD LYON 1
France
Address
43,Boulevard Du 11 Novembre 1918, 43
69622 Villeurbanne
UNIVERSITÀ DEGLI STUDI DI SIENA
Italy
Address
Via Ettore Bastianini 12
53100 Siena
University of Patras
Greece
Address
Riow
26110 Patras
VYGON SA
France
Address
5-11,Rue Adeline 5-11
95440 Ecouen
WAGENINGEN UNIVERSITY
Netherlands
Address
6,Dreijenlaan 6 Scheikundegebouw
6703 HB Wageningen